Merck & Co., Inc. (MRK) Return on Assets (ROA): 6.94%
Is Merck & Co., Inc.’s return on assets (ROA) high or low?
Merck & Co., Inc.'s return on assets (ROA) of 6.94% is 32% below its 5-year average of 10.28%, around the middle of its 5-year range (0.34%–14.62%).
As of Friday, June 12, 2026. 50.36% below its 12-month average of 13.98%.
MRK Return on Assets (ROA) Chart
MRK Average Return on Assets (ROA) Chart
MRK Current vs Average Return on Assets (ROA) Chart
MRK Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
6.94%
RETURN ON ASSETS (ROA) AVG TTM
13.98%
RETURN ON ASSETS (ROA) AVG 3Y
10.40%
RETURN ON ASSETS (ROA) AVG 5Y
10.28%
RETURN ON ASSETS (ROA) AVG 10Y
8.37%
RETURN ON ASSETS (ROA) AVG 15Y
7.56%
RETURN ON ASSETS (ROA) AVG 20Y
8.38%
CURRENT VS TTM AVG
-50.36%
CURRENT VS 3Y AVG
-33.27%
CURRENT VS 5Y AVG
-32.48%
CURRENT VS 10Y AVG
-17.08%
CURRENT VS 15Y AVG
-8.20%
CURRENT VS 20Y AVG
-17.21%
MRK Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $298.29B | 6.94% | 13.98% | 10.40% | 10.28% |
| AstraZeneca PLC (AZN) | $282.69B | 9.11% | 7.88% | 6.26% | 4.99% |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 3.85% | 4.36% | 6.27% | 6.84% |
| AbbVie Inc. (ABBV) | $397.12B | 2.67% | 3.16% | 4.61% | 4.90% |
| Amgen Inc. (AMGN) | $191.09B | 8.43% | 6.48% | 7.48% | 8.52% |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 6.05% | 6.31% | 6.46% | 7.20% |
| Gilead Sciences, Inc. (GILD) | $156.28B | 16.38% | 7.62% | 7.90% | 6.83% |
| Abbott Laboratories (ABT) | $156.15B | 5.68% | 11.99% | 10.28% | 9.45% |
| Pfizer Inc. (PFE) | $149.18B | 3.61% | 3.75% | 6.08% | 7.08% |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 14.81% | 13.09% | 12.00% | 11.68% |
Asset Efficiency
ROA
6.9%
ROE
19.5%
Merck & Co., Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Merck & Co., Inc. (MRK)?
- The return on assets (ROA) for MRK stock is 6.94%.
- Is Merck & Co., Inc.'s return on assets (ROA) high or low?
- Merck & Co., Inc.'s return on assets (ROA) of 6.94% is 32% below its 5-year average of 10.28%, around the middle of its 5-year range (0.34%–14.62%).
- What is the TTM average return on assets (ROA) for Merck & Co., Inc. (MRK)?
- The TTM average return on assets (ROA) for MRK stock is 13.98%.
- What is the 3Y average return on assets (ROA) for Merck & Co., Inc. (MRK)?
- The 3Y average return on assets (ROA) for MRK stock is 10.40%.
- What is the 5Y average return on assets (ROA) for Merck & Co., Inc. (MRK)?
- The 5Y average return on assets (ROA) for MRK stock is 10.28%.
- What is the 10Y average return on assets (ROA) for Merck & Co., Inc. (MRK)?
- The 10Y average return on assets (ROA) for MRK stock is 8.37%.
- What is the 15Y average return on assets (ROA) for Merck & Co., Inc. (MRK)?
- The 15Y average return on assets (ROA) for MRK stock is 7.56%.
- What is the 20Y average return on assets (ROA) for Merck & Co., Inc. (MRK)?
- The 20Y average return on assets (ROA) for MRK stock is 8.38%.
Merck & Co., Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 13.34% |
| 2024-12-31 | 14.62% |
| 2023-12-31 | 0.34% |
| 2022-12-31 | 13.30% |
| 2021-12-31 | 12.35% |
| 2020-12-31 | 7.72% |
| 2019-12-31 | 11.66% |
| 2018-12-31 | 7.53% |
| 2017-12-31 | 2.72% |
| 2016-12-31 | 4.11% |
| 2015-12-31 | 4.37% |
| 2014-12-31 | 12.14% |
| 2013-12-31 | 4.17% |
| 2012-12-31 | 5.81% |
| 2011-12-31 | 5.97% |
| 2010-12-31 | 0.81% |
| 2009-12-31 | 11.48% |
| 2008-12-31 | 16.54% |
| 2007-12-31 | 6.77% |
| 2006-12-31 | 9.95% |
| 2005-12-31 | 10.33% |
| 2004-12-31 | 13.69% |
| 2003-12-31 | 16.83% |
| 2002-12-31 | 15.03% |
| 2001-12-31 | 16.54% |
| 2000-12-31 | 17.09% |
| 1999-12-31 | 16.53% |
| 1998-12-31 | 16.48% |
| 1997-12-31 | 17.93% |
| 1996-12-31 | 15.98% |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis